The treatment market for active ankylosing spondylitis, which had been previously dominated by Tumor Necrosis Factor-alpha (TNF-α) inhibitors such as Humira and Remicade, is transforming. As of the 1st of this month, reimbursement has been applied and expanded to include major Janus Kinase (JAK) inhibitors and biologic agents for treating active ankylosing spondylitis; thereby, forecasting a likely surge in market competition.

According to the industry on the 16th, the two JAK inhibitors, Pfizer’s Xeljanz (tofacitinib) and AbbVie’s Rinvoq (upadacitinib), newly passed the reimbursement criteria for treating active ankylosing spondylitis. Eli Lilly’s Taltz (ixekizumab) and Novartis’ Cosentyx (secukinuma